- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
COVID-19 Bivalent Booster Shot Q&A for Clinicians
Emergency use authorizations for the Moderna and Pfizer-BioNTech COVID-19 vaccines have been amended by the US Food and Drug Administration to authorize single booster doses of new bivalent formulations of each that target the BA.4 and BA.5 omicron variants of the SARS-CoV-2 virus.
The recommendations for who is eligible for the revised vaccines and when may be causing some confusion among primary care patients—and clinicians as well.
Patient Care reviewed the updated Centers for Disease Control and Prevention’s Interim Clinical Considerations for COVID-19 Vaccination page to cull the most frequently asked questions primary care clinicians may have about the revised formulations and their administration. Following are the 7 questions—and answers—that cover the basics for both physicians and patients.
